Canaccord Genuity Reiterates a 'Buy' on Impax Laboratories (IPXL); Stock Can Run with 2H Catalysts
Tweet
Share
E-mailGet Alerts IPXL Hot Sheet
Price: $18.30 --0%
Rating Summary:
8 Buy, 15 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
8 Buy, 15 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Impax Laboratories (NASDAQ: IPXL) price target of $29.00.
Analyst, Randall Stanicky, said, "IPXL put up solid 2Q results that combined with several 2H catalyst updates helped boost the stock 8% off the recent pull-back. To be fair, sentiment into the quarter was low and short interest had spiked. Nevertheless, while visibility around back-half stock drivers has been fluid, they clearly remain and are likely coming in the next three months (namely manufacturing remediation and Rytary – IPX-066 PDUFA). We think that, combined with what is likely greater Street confidence in forecasts leaving today, can take the stock closer to pre-1Q levels of ~ $25 into back-half events that should be able to get the stock closer to our unchanged $29 target if they play through as expected."
For an analyst ratings summary and ratings history on Impax Laboratories click here. For more ratings news on Impax Laboratories click here.
Shares of Impax Laboratories closed at $22.22 yesterday.
Analyst, Randall Stanicky, said, "IPXL put up solid 2Q results that combined with several 2H catalyst updates helped boost the stock 8% off the recent pull-back. To be fair, sentiment into the quarter was low and short interest had spiked. Nevertheless, while visibility around back-half stock drivers has been fluid, they clearly remain and are likely coming in the next three months (namely manufacturing remediation and Rytary – IPX-066 PDUFA). We think that, combined with what is likely greater Street confidence in forecasts leaving today, can take the stock closer to pre-1Q levels of ~ $25 into back-half events that should be able to get the stock closer to our unchanged $29 target if they play through as expected."
For an analyst ratings summary and ratings history on Impax Laboratories click here. For more ratings news on Impax Laboratories click here.
Shares of Impax Laboratories closed at $22.22 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nutanix (NTNX) PT Raised to $80 at Oppenheimer Into EPS
- Jefferies Downgrades IDP Education (IEL:AU) (IDPUF) to Hold
- Marti Technologies (MRT) PT Raised to $6 at Benchmark on Stronger Growth, Improved Earnings Visibility
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
